查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2126398

免疫腫瘤生物標記市場：策略性洞察與預測（2026-2035）

Immuno-Oncology Biomarkers Market - Strategic Insights and Forecasts (2026-2035)
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計到 2026 年，免疫腫瘤生物標記市場規模將達到 88.1 億美元，到 2035 年將達到 242.3 億美元，複合年成長率為 11.9%。

免疫腫瘤生物標記市場正經歷顯著的變革，其驅動力包括：精準免疫療法模式轉移、免疫查核點抑制劑應用範圍的擴大以及基於生物標記的患者篩選日益複雜化。這一市場演變的特點在於，人們逐漸認知到分子、基因組、蛋白質組學和免疫相關的生物標記對於免疫療法的選擇、臨床反應預測、治療效果監測以及識別各種惡性腫瘤的抗藥性機制至關重要。次世代定序、免疫組織化學、數位病理學和液態生物檢體等先進分子技術的融合，使得生物標記評估更加全面和標準化。隨著免疫療法適應症的擴大，患者分層需要更加精準，促使醫療系統在診斷流程的早期階段納入全面的生物標記檢測。製藥公司正在採用以生物標記為中心的臨床試驗設計，因為有針對性的患者招募能夠提高治療反應率和臨床開發效率。監管機構正在擴大免疫療法伴隨診斷的批准範圍，因為標準化的生物標記評估有助於做出一致的臨床決策。隨著對多重基因組分析、空間生物學和人工智慧驅動的數位病理學的大量投資，免疫腫瘤生物標記正在成為精準腫瘤學和個人化癌症治療的關鍵組成部分。

市場促進因素

  • 伴隨診斷獲準數量的不斷成長是免疫腫瘤生物標記市場的主要驅動力。伴隨診斷在免疫療法的選擇中仍然至關重要，因為多種免疫查核點抑制劑在治療開始前都需要檢驗的生物標記評估。監管部門的批准將治療合格與診斷確認直接掛鉤，從而推動了標準化PD-L1、MSI/dMMR和TMB檢測在臨床實踐中的應用。隨著製藥公司不斷推出基於生物標記的免疫療法以適應更廣泛的癌症適應症，檢測網路也在擴展其檢驗的檢測能力。這種整合增強了診斷的應用，並支持在癌症治療過程中做出更精準的治療決策，從而永續地擴大免疫腫瘤生物標記的應用。此外，多基因組分析透過提高腫瘤表徵的準確性，進一步加速了市場成長。與單一分析物檢測相比，全面的分子分析能夠更全面地表徵腫瘤生物學。隨著臨床醫生對多種基因組和免疫生物標記同步評估的需求日益成長，多重定序工作流程正在醫療保健系統中得到應用。由於整合檢測能夠提高檢查室效率並減少組織消耗，診斷試劑生產商正不斷將定序、轉錄組學和免疫分析技術整合到一個統一的平台中。以生物標記為重點的臨床試驗正在透過製藥公司和診斷試劑生產商之間的合作，加速診斷技術的創新。由於免疫療法的反應在不同分子亞組間存在顯著差異，臨床開發越來越依賴由生物標記定義的患者群體。製藥公司正在將預測性生物標記納入臨床試驗方案，以改善患者選擇並提高臨床終點的達成率。診斷試劑開發商正繼續與治療試劑生產商合作，共同開發策略正在加速伴隨診斷的檢驗。人工智慧驅動的數位病理學正在改善生物標記的解讀和標準化。數位病理學透過提高病理檢查室間的可重複性，支持標準化的生物標記評估。醫療機構正在採用人工智慧輔助的圖像分析，因為定量解讀可以減少人工評分中存在的觀察者間差異。技術提供者不斷擴展計算病理學的功能，以改進 PD-L1 評估、免疫細胞定量和空間生物標記評估。

市場限制因素

  • 生物標記檢測缺乏全球標準化，導致分析性能和臨床解讀存在差異。缺乏統一的方案降低了可比性和臨床可靠性。部署先進定序平台和數位病理基礎設施的高昂成本限制了小規模醫療機構的應用。先進技術所需的大量資金投入對小規模機構而言是一個障礙。腫瘤異質性和不斷演變的免疫生物學持續限制單一生物標記在多種癌症類型中的預測準確性。腫瘤的生物學複雜性使得生物標記性能難以持續穩定地維持。區域法規的複雜性也給尋求將新型診斷解決方案商業化的製造商帶來了合規負擔。

對技術和生物標記類型的深入了解

  • 技術發展趨勢的特徵是整合分子譜分析、空間生物學和人工智慧驅動的數位病理學的重要性日益凸顯。 PD-L1表達生物標記是其中最成熟的領域之一，因為多種免疫查核點抑制劑的監管批准直接依賴檢驗的伴隨診斷測試。隨著PD-L1評估在非小細胞肺癌、尿路上皮癌、頭頸癌和其他惡性腫瘤的一線治療中變得越來越必要，臨床檢查室正在擴展標準化的免疫組化（IHC）工作流程。腫瘤突變負荷（TMB）和微衛星不穩定性/錯配修復缺陷（MSI/dMMR）的適應症正在擴展至組織非依賴性免疫治療。腫瘤浸潤淋巴細胞（TILs）、基因表現和新型聯合免疫譜的應用正在不斷推進。次世代定序（NGS）正在擴展全面的生物標記譜分析，並實現多種預測性生物標記的同步評估。 IHC在PD-L1蛋白表達評估中仍然至關重要。聚合酶鍊式反應（PCR）繼續支持特定生物標記的檢測。細分市場分析表明，非小細胞肺癌（NSCLC）是免疫查核點抑制劑的主要臨床應用領域，因為免疫檢查點抑制劑已成為第一線治療流程的重要組成部分。醫療機構正在將生物標記檢測擴展到多種癌症類型，包括黑色素瘤、乳癌直腸癌、乳腺癌、尿路上皮癌、胃癌和胃食道交界處癌以及頭頸部鱗狀細胞癌。患者篩檢仍然是最大的臨床應用領域，因為檢驗的生物標記可以確定多種癌症適應症患者合格免疫治療的條件。診斷檢查室是主要的終端使用者群體，醫院和學術研究機構也不斷擴展其偵測能力。隨著數位病理學透過提高病理檢查室間的可重複性來支援標準化生物標記評估，人工智慧的整合變得越來越重要。技術提供者正在不斷擴展計算病理學能力，以改進PD-L1評估、免疫細胞定量和空間生物標記評估。

競爭格局與策略展望

  • 競爭格局包括成熟的診斷和生命科學公司，以及專注於精準腫瘤學、分子診斷和液態生物檢體的供應商。羅氏透過羅氏製藥和羅氏診斷，仍然是最具策略整合能力的參與企業之一，它將藥物開發與全面的伴隨診斷產品組合相結合，從而能夠同時開發免疫療法和診斷檢測方法。安捷倫憑藉其在病理工作流程解決方案方面的強大專長脫穎而出，這些解決方案支持精準腫瘤學檢測、免疫組化試劑和分子診斷，並提供自動化染色系統、抗體、病理耗材和伴隨診斷檢測方法。凱傑憑藉其廣泛的分子診斷技術、樣本製備解決方案、PCR 檢測、NGS 工作流程和伴隨診斷產品組合，在精準腫瘤學領域佔據主導地位。 Illumina 作為基礎技術供應商，在全面的基因組分析中發揮關鍵作用，其 NGS 平台支援透過單一定定序工作流程檢測多種免疫腫瘤生物標記。 Guardant Health憑藉其在液態生物檢體技術領域的領先地位，確立了差異化優勢。該技術能夠為癌症患者提供非侵入性、全面性的基因組分析。 NeoGenomics則透過整合分子診斷、細胞遺傳學、流式細胞技術、免疫組化（IHC）、螢光原位雜合技術（FISH）和新一代定序（NGS）等技術，建構了綜合性的腫瘤檢查室服務模式，從而脫穎而出。兩家公司都在致力於透過多重基因組分析、太空生物學和人工智慧驅動的數位病理學等創新技術，拓展產品系列。由於需要開發伴隨診斷試劑以配合免疫療法，診斷試劑製造商和製藥公司之間的策略合作日益增加。近期一項重大進展是Agenus和Noetik宣布進行研究合作，利用Noetik的虛擬細胞模型，開發能夠預測botensilimab和valstilimab聯合治療療效的生物標記。休士頓大學也宣布，由CPRIT支持的核心設施將擴大德克薩斯州標靶蛋白質體學癌症生物標記篩檢的覆蓋範圍。地理擴張仍然是一項重要的策略重點，各公司都將目光投向了快速成長的亞太地區和醫療基礎設施正在發展的新興市場。

簡明結論

  • 免疫腫瘤生物標記市場預計將持續成長，這主要得益於免疫療法的擴展、技術創新和監管支持的推動。從單一標記診斷到整合多生物標記分析的轉變，標誌著精準腫瘤學領域的根本性變革。儘管標準化、部署成本和腫瘤異質性等挑戰依然存在，但對技術、夥伴關係和證據產生的策略性投資正為市場領導提供持續的競爭優勢。長期市場前景依然樂觀，免疫腫瘤生物標記將發展成為精準腫瘤學的關鍵組成部分，在全球醫療保健系統中支持患者選擇、治療最佳化和改善臨床療效。

本報告的主要特點

  • 深入分析：對各個地區、客戶群、政策、社會經濟因素、消費者偏好和產業部門進行詳細的市場洞察。
  • 競爭格局：我們了解主要參與者的策略舉措，並確定最佳的市場進入方式。
  • 市場促進因素與未來趨勢：我們評估影響市場的關鍵成長要素和新興趨勢。
  • 實用建議：我們支援制定策略決策以開發新的收入來源。
  • 適合各類讀者：非常適合新創公司、研究機構、顧問公司、中小企業和大型企業。

公司對我們報告的使用

  • 產業和市場洞察、機會評估、產品需求預測、打入市場策略、區域擴張、資本投資決策、監管分析、新產品開發和競爭情報。

報告範圍

  • 歷史資料涵蓋 2021 年至 2024 年，基準年為 2025 年，預測期為 2026 年至 2035 年。
  • 成長機會、挑戰、供應鏈前景、法律規範與趨勢分析
  • 競爭對手定位、策略、市場佔有率評估和貿易分析
  • 按細分市場和區域分類的銷售成長和預測評估
  • 公司簡介，包括策略、產品、財務狀況和主要發展動態。

目錄

第1章執行摘要

  • 市場概述
  • 主要發現
  • 分析師意見
  • 策略建議

第2章：調查方法

  • 調查設計
  • 資料收集和調查方法
  • 市場規模估算
  • 預測模型
  • 先決條件和限制

第3章 全球腫瘤免疫生物標記市場：概述、市場規模與預測

  • 市場定義和範圍
  • 免疫腫瘤生物標記行業概覽
  • 產業變化
  • 主要市場趨勢
  • 市場規模表現分析
  • 市場預測
  • 癌症負擔及基於生物標記的免疫療法的臨床需求
  • 生物標記檢測現狀
  • 患者族群和生物標記合格分析
  • 伴隨診斷的現狀
  • 基於生物標記的治療決策框架

第4章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰

第5章 行業情勢

  • 產業價值鏈分析
  • 定價分析
  • 還款狀態

第6章：創新趨勢

  • 新型生物標記技術
  • 產品創新
  • 臨床試驗分析
  • 管道分析
  • 將人工智慧整合到免疫腫瘤學生物標記的發現和解讀中
  • 多體學與空間生物學的整合

第7章 監理情勢

  • 法律規範
  • 核准流程
  • 合規要求

第8章：全球腫瘤免疫生物標記市場：展望分析

  • 分析：依生物標記類型
  • 分析：按技術平台
  • 分析：依樣本類型
  • 分析：按癌症適應症
  • 分析：透過臨床應用
  • 分析：透過調查方法

第9章 全球腫瘤免疫生物標記市場：細分市場分析

  • 依生物標誌類型
    • PD-L1表達生物標記
    • 腫瘤突變負荷（TMB）
    • 微衛星不穩定性（MSI）/錯配修復缺陷（dMMR）
    • 腫瘤浸潤淋巴細胞（TILs）
    • 基因表現特徵
    • HLA和新抗原生物標記物
    • 其他
  • 透過技術平台
    • 免疫組織化學（IHC）
    • 次世代定序（NGS）
    • 聚合酵素鏈鎖反應（PCR）
    • 螢光原位雜合反應（FISH）
    • 其他
  • 依樣本類型
    • 基於組織的檢測
    • 血液來源（液態生物檢體）
    • 其他生物檢體
  • 癌症適應症類型
    • 非小細胞肺癌
    • 黑色素瘤
    • 尿路上皮癌
    • 乳癌
    • 結腸癌
    • 胃癌和胃食道癌
    • 頭頸部鱗狀細胞癌
    • 其他癌症
  • 臨床應用
    • 患者選擇
    • 預測治療反應
    • 預後評估
    • 疾病監測和復發評估
  • 最終用戶
    • 醫院
    • 診斷檢查室
    • 學術研究機構
    • 其他

第10章 全球免疫腫瘤生物標記市場：區域分析

  • 北美洲
  • 歐洲
  • 亞太地區
  • 南美洲
  • 中東和非洲

第11章 全球免疫腫瘤生物標記市場：國家分析

  • 美國
  • 加拿大
  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙
  • 日本
  • 中國
  • 韓國
  • 印度
  • 澳洲
  • 巴西

第12章 競爭格局

  • 市佔率分析
  • 策略趨勢
  • 併購、合作與聯盟
  • 新產品發布

第13章：公司簡介

  • F. Hoffmann-La Roche Ltd.
  • Agilent Technologies, Inc.
  • QIAGEN NV
  • Illumina, Inc.
  • Natera, Inc
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • Guardant Health, Inc.
  • NeoGenomics Laboratories, Inc.
  • Myriad Genetics, Inc.

第14章 全球腫瘤免疫生物標記市場：商業預測分析

  • 按適應症評估癌症治療的商業性機會。
  • 伴隨診斷銷售預測

第15章 投資與資金籌措分析

  • 創業投資趨勢
  • 政府資金
  • 研發投資

第16章：未來展望

  • 主要成長機遇
  • 未來產業趨勢
簡介目錄
Product Code: KSI-009110

The Immuno-Oncology Biomarkers Market is predicted to increase at a CAGR of 11.9% from a market size of USD 8.81 billion in 2026 to USD 24.23 billion in 2035.

The immuno-oncology biomarkers market is undergoing significant transformation driven by the paradigm shift toward precision immunotherapy, the expanding landscape of immune checkpoint inhibitors, and the growing complexity of biomarker-guided patient selection. The market's evolution is characterized by the recognition that molecular, genomic, proteomic, and immune-based biomarkers are essential for guiding immunotherapy selection, predicting clinical response, monitoring treatment effectiveness, and identifying mechanisms of resistance across various malignancies. The convergence of advanced molecular technologies, including next-generation sequencing, immunohistochemistry, digital pathology, and liquid biopsy, is enabling more comprehensive and standardized biomarker assessment. Healthcare systems are integrating comprehensive biomarker testing earlier within diagnostic pathways because expanding immunotherapy indications require increasingly precise patient stratification. Pharmaceutical companies are incorporating biomarker-enriched clinical trial designs because targeted patient recruitment improves therapeutic response rates and clinical development efficiency. Regulatory agencies are expanding companion diagnostic approvals alongside immunotherapies because standardized biomarker assessment supports consistent clinical decision-making. The market is witnessing significant investment in multiplex genomic profiling, spatial biology, and AI-enabled digital pathology, positioning immuno-oncology biomarkers as a critical component of precision oncology and personalized cancer care.

Market Drivers

  • The expanding companion diagnostic approvals represent the primary driver for the immuno-oncology biomarkers market. Companion diagnostics remain fundamental to immunotherapy selection because multiple immune checkpoint inhibitors require validated biomarker assessment before treatment initiation. Clinical practice is increasingly incorporating standardized PD-L1, MSI/dMMR, and TMB testing because regulatory approvals directly link therapeutic eligibility with diagnostic confirmation. Laboratory networks are expanding validated testing capabilities as pharmaceutical companies continue introducing biomarker-driven immunotherapies across additional cancer indications. This integration strengthens diagnostic utilization while supporting precision treatment decisions throughout oncology care, resulting in sustained growth in immuno-oncology biomarker utilization. Multiplex genomic profiling is further accelerating market growth through improved tumor characterization. Comprehensive molecular profiling provides broader characterization of tumor biology than single-analyte testing. Healthcare systems are adopting multiplex sequencing workflows because clinicians increasingly require simultaneous evaluation of multiple genomic and immune biomarkers. Diagnostic manufacturers continue integrating sequencing, transcriptomics, and immune profiling technologies into unified platforms because consolidated testing improves laboratory efficiency and reduces tissue consumption. Biomarker-enriched clinical trials are accelerating diagnostic innovation through pharmaceutical-diagnostic collaboration. Clinical development increasingly depends on biomarker-defined patient populations because immunotherapy response varies substantially across molecular subgroups. Pharmaceutical sponsors are incorporating predictive biomarkers into trial protocols to improve patient selection and clinical endpoint achievement. Diagnostic developers continue collaborating with therapeutic manufacturers because co-development strategies accelerate companion diagnostic validation. AI-enabled digital pathology is enhancing biomarker interpretation and standardization. Digital pathology supports standardized biomarker assessment by improving reproducibility across pathology laboratories. Healthcare institutions are integrating AI-assisted image analysis because quantitative interpretation reduces observer variability associated with manual scoring. Technology providers continue expanding computational pathology capabilities to improve PD-L1 assessment, immune cell quantification, and spatial biomarker evaluation.

Market Restraints

  • Limited global standardization across biomarker assays continues creating variability in analytical performance and clinical interpretation. The lack of harmonized protocols reduces comparability and clinical confidence. High implementation costs for advanced sequencing platforms and digital pathology infrastructure restrict adoption among smaller healthcare institutions. The significant financial investment required for advanced technologies creates barriers for smaller facilities. Tumor heterogeneity and evolving immune biology continue limiting the predictive accuracy of individual biomarkers across several cancer types. The biological complexity of tumors creates challenges for consistent biomarker performance. Regulatory complexities across different jurisdictions create compliance burdens for manufacturers seeking to commercialize new diagnostic solutions.

Technology and Biomarker Type Insights

  • The technology landscape is characterized by the growing importance of integrated molecular profiling, spatial biology, and AI-enabled digital pathology. PD-L1 expression biomarkers constitute one of the most established segments because regulatory approvals for multiple immune checkpoint inhibitors directly depend on validated companion diagnostic testing. Clinical laboratories are expanding standardized IHC workflows as first-line immunotherapy recommendations increasingly require PD-L1 assessment across non-small cell lung cancer, urothelial carcinoma, head and neck cancer, and additional malignancies. TMB and MSI/dMMR are expanding for tissue-agnostic immunotherapy indications. TILs, gene expression signatures, and emerging composite immune signatures are gaining adoption. NGS is expanding comprehensive biomarker profiling and enabling simultaneous evaluation of multiple predictive biomarkers. IHC remains essential for PD-L1 protein expression assessment. PCR continues supporting focused biomarker detection. The segment analysis reveals that NSCLC represents the leading clinical application because immune checkpoint inhibitors have become integral components of first-line treatment algorithms. Healthcare providers are expanding biomarker testing across melanoma, colorectal cancer, breast cancer, urothelial carcinoma, gastric and gastroesophageal cancers, and head and neck squamous cell carcinoma. Patient selection remains the largest clinical application because validated biomarkers determine eligibility for immunotherapy across multiple cancer indications. Diagnostic laboratories represent the leading end-user segment, with hospitals and academic research institutes expanding testing capabilities. The integration of AI is becoming increasingly important because digital pathology supports standardized biomarker assessment by improving reproducibility across pathology laboratories. Technology providers continue expanding computational pathology capabilities to improve PD-L1 assessment, immune cell quantification, and spatial biomarker evaluation.

Competitive and Strategic Outlook

  • The competitive landscape features established diagnostics and life science companies alongside specialized precision oncology, molecular, and liquid biopsy providers. Roche remains one of the most strategically integrated participants because it combines pharmaceutical development with a comprehensive companion diagnostics portfolio through Roche Pharmaceuticals and Roche Diagnostics, enabling simultaneous development of immunotherapies and diagnostic assays. Agilent differentiates itself through its strong expertise in pathology workflow solutions, immunohistochemistry reagents, and molecular diagnostics that support precision oncology testing, providing automated staining systems, antibodies, pathology consumables, and companion diagnostic assays. QIAGEN occupies a prominent position in precision oncology because of its broad portfolio of molecular diagnostic technologies, sample preparation solutions, PCR assays, NGS workflows, and companion diagnostics. Illumina serves as a foundational technology provider for comprehensive genomic profiling because its NGS platforms support detection of multiple immuno-oncology biomarkers through a single sequencing workflow. Guardant Health has established a differentiated position through its leadership in liquid biopsy technologies that enable non-invasive comprehensive genomic profiling for cancer patients. NeoGenomics differentiates itself through a comprehensive oncology testing service model that combines molecular diagnostics, cytogenetics, flow cytometry, IHC, FISH, and NGS within an integrated laboratory network. Companies are pursuing product portfolio expansion through innovation in multiplex genomic profiling, spatial biology, and AI-enabled digital pathology. Strategic collaborations between diagnostic manufacturers and pharmaceutical companies are increasing, driven by the need for companion diagnostic development alongside immunotherapies. Recent key developments include Agenus and Noetik announcing a research collaboration to develop predictive biomarkers for response to botensilimab plus balstilimab using Noetik's virtual cell foundation models. The University of Houston announced the CPRIT-backed core will expand access to targeted proteomic cancer biomarker screening in Texas. Geographic expansion remains a key strategic priority, with companies targeting rapidly growing Asia Pacific and emerging markets where healthcare infrastructure is expanding.

Short Conclusion

  • The immuno-oncology biomarkers market is positioned for sustained growth driven by the convergence of immunotherapy expansion, technological innovation, and regulatory support. The transition from single-marker diagnostics toward integrated multi-biomarker profiling represents a fundamental shift in precision oncology. While challenges related to standardization, implementation costs, and tumor heterogeneity persist, strategic investments in technology, partnerships, and evidence generation are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with immuno-oncology biomarkers evolving into a critical component of precision oncology, supporting patient selection, treatment optimization, and improved clinical outcomes across global healthcare systems.

Key Benefits of this Report

  • Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
  • Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
  • Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
  • Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
  • Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

  • Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

  • Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
  • Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
  • Competitive positioning, strategies, and market share evaluation, and trade analysis
  • Revenue growth and forecast assessment across segments and regions
  • Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

  • 1.1 Market Snapshot
  • 1.2 Key Findings
  • 1.3 Analyst Insights
  • 1.4 Strategic Recommendations

2. Research Methodology

  • 2.1 Research Design
  • 2.2 Data Collection Methodology
  • 2.3 Market Size Estimation
  • 2.4 Forecasting Model
  • 2.5 Assumptions & Limitations

3. Global Immuno-Oncology Biomarkers Market Overview, Size & Forecast

  • 3.1 Market Definition & Scope
  • 3.2 Immuno-Oncology Biomarkers Industry Overview
  • 3.3 Industry Evolution
  • 3.4 Key Market Trends
  • 3.5 Historical Market Size Analysis (2021-2025)
  • 3.6 Market Forecast (2026-2035)
  • 3.7 Cancer Burden and Clinical Need for Biomarker-Guided Immunotherapy
  • 3.8 Biomarker Testing Landscape
  • 3.9 Patient Population and Biomarker Eligibility Analysis
  • 3.10 Companion Diagnostics Landscape
  • 3.11 Biomarker-Driven Treatment Decision Framework

4. Market Dynamics

  • 4.1 Market Drivers
  • 4.2 Market Restraints
  • 4.3 Market Opportunities
  • 4.4 Market Challenges

5. Industry Landscape

  • 5.1 Industry Value Chain Analysis
  • 5.2 Pricing Analysis
  • 5.3 Reimbursement Landscape

6. Innovation Landscape

  • 6.1 Emerging Biomarker Technologies
  • 6.2 Product Innovation
  • 6.3 Clinical Trial Analysis
  • 6.4 Pipeline Analysis
  • 6.5 AI Integration in Immuno-Oncology Biomarker Discovery and Interpretation
  • 6.6 Multi-Omics and Spatial Biology Integration

7. Regulatory Landscape

  • 7.1 Regulatory Framework
  • 7.2 Approval Pathways
  • 7.3 Compliance Requirements

8. Global Immuno-Oncology Biomarkers Market Landscape Analysis

  • 8.1 Analysis by Biomarker Type
  • 8.2 Analysis by Technology Platform
  • 8.3 Analysis by Sample Type
  • 8.4 Analysis by Cancer Indication
  • 8.5 Analysis by Clinical Application
  • 8.6 Analysis by Testing Methodology

9. Global Immuno-Oncology Biomarkers Market Segment Analysis (2021-2035)

  • 9.1 By Biomarker Type
    • 9.1.1 PD-L1 Expression Biomarkers
    • 9.1.2 Tumor Mutational Burden (TMB)
    • 9.1.3 Microsatellite Instability (MSI) / Mismatch Repair Deficiency (dMMR)
    • 9.1.4 Tumor-Infiltrating Lymphocytes (TILs)
    • 9.1.5 Gene Expression Signatures
    • 9.1.6 HLA and Neoantigen Biomarkers
    • 9.1.7 Others
  • 9.2 By Technology Platform
    • 9.2.1 Immunohistochemistry (IHC)
    • 9.2.2 Next-Generation Sequencing (NGS)
    • 9.2.3 Polymerase Chain Reaction (PCR)
    • 9.2.4 Fluorescence In Situ Hybridization (FISH)
    • 9.2.5 Others
  • 9.3 By Sample Type
    • 9.3.1 Tissue-Based Testing
    • 9.3.2 Blood-Based (Liquid Biopsy)
    • 9.3.3 Other Biological Samples
  • 9.4 By Cancer Indication
    • 9.4.1 Non-Small Cell Lung Cancer
    • 9.4.2 Melanoma
    • 9.4.3 Urothelial Carcinoma
    • 9.4.4 Breast Cancer
    • 9.4.5 Colorectal Cancer
    • 9.4.6 Gastric and Gastroesophageal Cancers
    • 9.4.7 Head and Neck Squamous Cell Carcinoma
    • 9.4.8 Other Cancer Types
  • 9.5 By Clinical Application
    • 9.5.1 Patient Selection
    • 9.5.2 Treatment Response Prediction
    • 9.5.3 Prognostic Assessment
    • 9.5.4 Disease Monitoring and Recurrence Assessment
  • 9.6 By End User
    • 9.6.1 Hospitals
    • 9.6.2 Diagnostic Laboratories
    • 9.6.3 Academic & Research Institutes
    • 9.6.4 Others

10. Global Immuno-Oncology Biomarkers Market Geographical Analysis (2021-2035)

  • 10.1 North America
  • 10.2 Europe
  • 10.3 Asia-Pacific
  • 10.4 South America
  • 10.5 Middle East & Africa

11. Global Immuno-Oncology Biomarkers Market Country Analysis (2021-2035)

  • 11.1 United States
  • 11.2 Canada
  • 11.3 Germany
  • 11.4 United Kingdom
  • 11.5 France
  • 11.6 Italy
  • 11.7 Spain
  • 11.8 Japan
  • 11.9 China
  • 11.10 South Korea
  • 11.11 India
  • 11.12 Australia
  • 11.13 Brazil

12. Competitive Landscape

  • 12.1 Market Share Analysis
  • 12.2 Strategic Developments
  • 12.3 Mergers & Acquisitions, Partnerships & Collaborations
  • 12.4 Product Launches

13. Company Profiles

  • 13.1 F. Hoffmann-La Roche Ltd.
    • 13.1.1 Company Overview
    • 13.1.2 Financials
    • 13.1.3 Product Portfolio
    • 13.1.4 Recent Developments
  • 13.2 Agilent Technologies, Inc.
  • 13.3 QIAGEN N.V.
  • 13.4 Illumina, Inc.
  • 13.5 Natera, Inc
  • 13.6 Bio-Rad Laboratories, Inc.
  • 13.7 Danaher Corporation
  • 13.8 Guardant Health, Inc.
  • 13.9 NeoGenomics Laboratories, Inc.
  • 13.10 Myriad Genetics, Inc.

14. Global Immuno-Oncology Biomarkers Market Commercial Forecast Analysis

  • 14.1 Forecast by Commercial Biomarker Category
    • 14.1.1 PD-L1 Biomarker Tests
    • 14.1.2 TMB Assays
    • 14.1.3 MSI/dMMR Tests
    • 14.1.4 Comprehensive Genomic Profiling Assays
    • 14.1.5 Liquid Biopsy-Based Immuno-Oncology Biomarker Tests
  • 14.2 Commercial Opportunity Assessment by Cancer Indication
  • 14.3 Companion Diagnostics Revenue Outlook

15. Investment & Funding Analysis

  • 15.1 Venture Capital Trends
  • 15.2 Government Funding
  • 15.3 R&D Investments

16. Future Outlook

  • 16.1 Key Growth Opportunities
  • 16.2 Future Industry Trends